Review Article Clinicopathological and prognostic significance of TFF3 immunohistochemical expression in gastric cancer: a meta-analysis
Int J Clin Exp Med
The molecular biomarker trefoil factor 3 (TFF3) is reported that plays important role in the pathogenesis of gastric cancer (GC). However, it is still controversial whether TFF3 expression can be regarded as a prognostic factor for GC patients. Here we performed a meta-analysis to evaluate the value of TFF3 for its survival prognostic indicator and predictive correlation with clinicopathological features in GC. Eligible studies were identified from PubMed, Embase and Web of science. The odd
... cience. The odd sratio (OR) and hazard ration (HR) with their 95% confidence intervals (CI) were calculated using Review Manager version 5.3. Finally 8 studies involving 1170 patients with GC were included in this meta-analysis. Our results showed that TFF3 overexpression was significantly associated with poorer overall survival (HR=1.86, 95% CI=1.26-2.74, P=0.002) and disease free survival (HR=2.29, 95% CI=1.48-3.56, P=0.0002) in GC. Moreover, TFF3 overexpression was also significantly associated with histological type (OR=1.69, 95% CI=1.31-2.17, P<0.0001), lymph node metastasis (OR=2.05, 95% CI=1.61-2.62, P<0.00001), the depth of invasion (OR=1.37, 95% CI=0.99-1.88, P=0.05) and tumor TNM stage (OR=2.00, 95% CI=1.36-2.97, P=0.0005). However, none of other demographic parameters such as age and gender were associated with TFF3 expression. In conclusions, our results indicating that TFF3 overexpression could be regarded as a novel prognostic factor for gastric cancer patients, which may help to better guide clinical decision-making.